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To improve the efficacy of T cell–based vaccination, we pursued the
principle that CD4+ T cells provide help for functional CD8+ T cell
immunity. To do so, we administered HIV gag to mice successively
as protein and DNA vaccines. To achieve strong CD4+ T cell immun-
ity, theprotein vaccinewas targeted selectively toDEC-205, a recep-
tor for antigenpresentation on dendritic cells. This targetinghelped
CD8+ T cell immunity develop to a subsequent DNA vaccine and
improved protection to intranasal challengewith recombinant vac-
cinia gag virus, includingmore rapid accumulation of CD8+ T cells in
the lung. The helper effect of dendritic cell-targeted protein vaccine
wasmimickedby immunizationwith specificMHC II bindingHIVgag
peptides but not peptides from a disparate Yersinia pestismicrobe.
CD4+ helper cells upon adoptive transfer allowedwild-type, but not
CD40−/−, recipient mice to respond better to the DNA vaccine. The
transfer also enabled recipients to more rapidly accumulate gag-
specific CD8+ T cells in the lung following challenge with vaccinia
gag virus. Thus, complementary prime boost vaccination, in which
prime and boost favor distinct types of T cell immunity, improves
plasmidDNA immunization, includingmobilizationofCD8+T cells to
sites of infection.
complementary | prime | boost | vaccination | helper
To improve the efficacy of safe vaccines against global patho-gens like HIV-1, “heterologous prime-boost” strategies are
being tested, in particular priming with a DNA vaccine and
boosting with a recombinant viral vector (1, 2). During heterolo-
gous prime-boosting, vaccine antigens are introduced in different
vectors to reduce the risk of anti-vector immunity; e.g., adenoviral
vectors quickly induce neutralizing antibodies minimizing the
response to multiple doses. Here, we have pursued a “comple-
mentary” prime boost vaccination strategy, in which the two vac-
cines induce different types of immunity and no microbial vectors
are required.
We previously reported that a protein-based vaccine becomes
more immunogenic for mice when it is directly targeted to
dendritic cells (DCs), the principal antigen-presenting cells for
initiating T cell immunity (3), along with a suitable adjuvant to
stimulate DC maturation. Selective and efficient antigen tar-
geting to DCs was achieved by introducing HIV gag (4, 5) into a
monoclonal antibody (mAb) to a DC-restricted, antigen uptake
receptor, DEC-205 or CD205. Synthetic double-stranded RNA,
polyIC, proved to be an effective adjuvant for this protein vac-
cine (5). Nevertheless, the achieved immunity was primarily
comprised of Th1-type CD4+ T cells whereas, in contrast, DNA-
and adenoviral vector-based vaccines induced higher CD8+ T
cell frequencies (4).
It is known that CD4+ T cells provide essential help for gen-
erating CD8+ T cell responses (6–11). Here, we will show that
protective CD8+T cell immunity to aDNAvaccine is improved by
priming a helper T cell response with a DC-targeted protein vac-
cine. One component of the improved protection is a more rapid
accumulation of gag-specific CD8+ T cells to a mucosal infection
challenge site.
Results
DC-Targeted Protein Enhances Protection Afforded by a DNA Vaccine.
To test the protection afforded by protein and DNA vaccines, we
first compared two doses of DC-targeted, DEC-gag protein vac-
cine to two doses of gag plasmid DNA vaccine, given 1 month
apart, and we used a higher intranasal (i.n.) dose of challenge virus
than our prior studies (4, 5). Both protein and DNA forms of
vaccination induced protection against weight loss (Fig. S1A) and
an ∼100-fold reduction to challenge recombinant vaccinia virus
(Fig. 1A; compare orange and green with black).
Next, to try to improve protective immunity, we primedmice with
a single dose of DEC-targeted gag protein vaccine followed by a
boost with gag plasmid DNA 4–8 weeks later. Twelve weeks after
boosting, mice were challenged with recombinant vaccinia gag,
whereupon weight loss was monitored daily and lung virus titers
determinedasdescribed (4, 5, 12).Again,mice receiving twodosesof
DNA exhibited some protection against weight loss (Fig. S1B,
orange) and also an ∼100-fold reduction in virus titers (Fig. 1B,
orange).A singledoseofDNAvaccinedidnotprotect againstweight
loss and reduced virus titers only by 10-fold (Fig. 1B, red). However,
priming with DEC-gag plus polyIC protein vaccine followed by
plasmid DNA vaccine provided superior protection against weight
loss to two DNA vaccines (Fig. 1B, *) and reduced virus titers in the
lung by an average of 5,000-fold in three experiments (Fig. 1B, dark
blue),which titerswere significantly lower thanmicevaccinated twice
with DNA (P < 0.005). The control for this and the following
experiments was a control Ig (not binding to DCs) gag protein vac-
cine followed by a single DNA boost, but this control prime boost
strategy offered only 1 log of protection (Fig. 1B, turquoise).Wewill
use the term “complementary” prime boost to describe DEC-gag
protein prime plus DNA boost, because we will show that each part
of the vaccine induces a distinct type of immune response.
T Cells Provide Protection After a Complementary Protein Prime-DNA
Boost Vaccine. To assess the contribution of T cells to protective
immunity, we treatedmice with either rat IgG control mAb or with
depleting mAbs to CD4 and CD8 before the i.n. challenge with
recombinant vaccinia gag virus.We verified thesemAbs selectively
depleted CD4+ and CD8+ CD3+ T cells. In addition, we found
that treatment of mice with control mAb did not interfere with the
observed 3 logs of protection afforded by the complementary
prime boost vaccine to vaccinia gag challenge (Fig. 2A Upper Left,
dark blue bar). However, depletion of either CD4+ or CD8+ T
cells reduced protection significantly (10- to 30-fold) for the mice
vaccinated with the DEC-gag prime DNA boost regimen but did
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not completely eliminate protection (Fig. 2A, two right bars). We
then treated vaccinated mice with either control Ig or a combi-
nation of mAbs to CD4 and CD8 (Fig. 2B, Left and Right).
Depletion of both CD4+ and CD8+ T cells before challenge
eliminated protection from weight loss (Fig. S1 C and D) and
increased lung virus titers (Fig. 2B, compare dark blue bars in Left
and Right). Therefore, the superior protection from comple-
mentary prime boost requires both CD4+ and CD8+ T cells.
Protein Priming Improves CD8+ T Cell Immunity to a DNA Vaccine. To
assess T cell immunity after vaccination with DEC-targeted gag
protein prime followed by gag DNA boost, we measured CD4+
and CD8+, gag-specific T cells at the single-cell level. One dose of
DNA elicited weak CD4+ and CD8+ immunity (Fig. 3 A–C, red
second row of data) whereas two doses induced a stronger
response (orange, third row of data). Prior data had shown that
one dose of DEC-targeted gag protein vaccine, together with
polyIC, induced weak CD4+ T cell immunity, whereas two doses
led to strong but primarily CD4+ T cell immunity (5) (and see
below). In three experiments, priming with one dose of a DC
targeted protein vaccine, but not nontargeted control Ig-gag vac-
cine, resulted in strong combined CD4+ and CD8+ T cell
immunity to a single dose of DNA vaccine (Fig. 3 A–C, compare
fourth and fifth rows, turquoise and dark blue). IFN-γ production
by CD4+ T cells following complementary prime boost also was
significantly higher than with two doses of DNA [Fig. 3, ** (P <
0.01)]. For mice primed with either two doses of DNA or com-
plementary prime boost, the gag-specific CD8+ T cells were also
capable of proliferating toHIVgag (Fig. 3D, *).However,CD4+T
cells immunized with the complementary prime boost approach
expanded significantly better than CD4+ T cells immunized with
two doses of DNA [Fig. 3D, *, open bars (P < 0.05)]. The gag-
specific CD4+ and CD8+ T cells persisted at least 4 months after
boosting in two long-term experiments (Fig. 3E, dark blue). Thus,
complementary prime boosting provides improved and long-lived
CD4+ and CD8+ T cell immunity to one dose of DNA vaccine.
Complementary Protein Prime-DNA Boost Allows for More Rapid
Accumulation of CD8+ T Cells to an Infection Challenge Site. Because
the above studies did not reveal a major quantitative difference in
CD8+ T cells induced by two doses of DNA (“homologous” prime
boost) vs. complementary prime boost, we asked whether the
primingwithDECgag vaccine improved the quality of theCD8+T
cell response by examining the rapidity with which gag-specific
CD8+ T cells were mobilized to a site of infection. In three
experiments, 120 days after vaccination, we challenged the mice
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Fig. 1. DC-targeted protein vaccine enhances protection from DNA vaccine.
(A) Groups of five female 6- to 10-week-old CxB6 F1 mice were primed and
boosted with protein (5 μg of anti-DEC HIV gag p41 plus 50 μg of polyIC) or
DNA vaccine (10 μg of HIV gag p41 DNA) i.m. 8 weeks apart. Twelve weeks
after the boost, a lethal dose (105 PFU) of recombinant vaccinia gag was
given i.n., and vaccinia virus titers in the lung (PFU/lung) were measured 7
days later. (B) As in (A), but complementary protein-prime DNA-boost vac-
cination (blue) was evaluated to induce protection as monitored by lung



















































































Fig. 2. CD4+ and CD8+ T cells protect mice after protein-prime DNA-boost vaccine. (A) Mice vaccinated as indicated on the x axis and Fig. 1 were treated with
control rat Ig or depleting antibodies to CD4 or CD8 at days −3, −2, and −1 before airway challenge with recombinant vaccinia gag virus (mean of two
experiments). (B) As in (A), mice were treated with control rat IgG (Left) or depleted of both CD4+ and CD8+ T cells (Right) before challenge with vaccinia gag
and measurement of vaccinia virus titers (PFU/lung).

































challenge infection, the lungs, as well as the spleen 4 and 7 days
later. Priming with DEC-gag p41 plus polyIC followed by boosting
withonedose ofDNA led to abetter accumulation ofCD8+Tcells
to the lung (P = 0.05) than a single dose or two doses of DNA
vaccine (Fig. 4A, compare lung day 4 data at arrows). To establish
that the accumulation of gag-reactive CD8+ T cells in the lungs
was specific to vaccine antigen, we showed that gag-reactive cells
accumulated whenmice were challenged with vaccinia gag but not
vaccinia OVA (Fig. 4B). Therefore, complementary prime boost
vaccination leads to more rapid accumulation of CD8+ T cells
upon vaccinia gag challenge, and this is gag antigen-dependent not
vaccinia "inflammation"- or infection-dependent.
CD4 Restricted HIV gag Peptides Provide Help for HIV gag DNAVaccine.
To test whether priming with DEC-gag p41 protein could be
replaced with previously defined gag peptides that are recognized
by primedCD4+T cells (4), we synthesized three of these peptides
(C57BL/6 pool 1, peptide #6, amino acids 145–159, QAISP-
RTLNAWVKVV; B6 pool 4, peptide #8, amino acids 297–311,
VDRFYKTLRAEQASQ; Balb/C pool 3, peptide #10, amino
acids 257–271, PVGEIYKRWIILGLN) and used them to prime
and boost CxB6 F1 mice. In parallel, we primed mice with a single
peptide (GHQAAMQMLKETINE, amino acids 193–207) that
includes a nanomer recognized by gag-specific CD8+ T cells
(AMQMLKETI) presented on H-2d, as well as CD4-restricted
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Fig. 3. Complementary protein prime DNA boost vaccination induces combined and durable CD4+ and CD8+ T cell immunity. (A) Female CxB6 F1 mice were
vaccinated as in Fig. 1. Thirty days after the DNA boost, bulk splenocytes were assessed for T cell immunity. (A and B) Splenocytes were restimulated either
with unreactive peptides or with an HIV gag peptide mix, and IFN-γ production in response to peptide was evaluated by intracellular cytokine staining 6 h
later in CD4+ (A) or CD8+ (B) CD3+ T cells. (C) HIV gag-specific CD8+ T cells were enumerated by binding of gag tetramers. (D) HIV gag-dependent T cell
proliferation and IFN-γ production was measured in CFSE-labeled splenocytes restimulated for 4 days with gag-specific peptides (or nonspecific control
peptides), followed by intracellular staining for IFN-γ in CFSE-low CD4+ and CD8+ T cells. All data are mean ± SD of three experiments, each involving five F1
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Fig. 4. Complementary protein prime DNA boost vaccine allows for more rapid accumulation of CD8+ T cells to an infection challenge site. As in Fig. 3, mice
were vaccinated (y axis) and 90 days after the boost challenged with a lethal dose of vaccinia gag i.n. At day 4 and day 7, lungs were dissociated to enumerate
HIV gag-specific tetramer binding cells. (A) A rapid accumulation of specific CD8+ T cells in the lungs after DC-targeted protein prime-DNA boost vaccine.
Illustrative FACS data are in Fig. S3. Arrows point to rapidly accumulating gag-specific CD8+ T cells early (day 4) in mice challenged after two doses of DNA
vaccine or complementary prime-boost vaccine. Shown are means of two experiments. (B) In HIV gag-vaccinated mice, gag-specific CD8+ T cells accumulate
when mice are challenged with vaccinia gag (Left) but not vaccinia-OVA (Right).









































pestis as described (13). As expected, the peptides primed themice
in a specific way; i.e., CD4-negative T cells were primed to CD8-
restricted gag peptides (Fig. S2, arrow second row) whereas CD4+
T cells were primed selectively to either LcrV or gag CD4-
restricted peptides (Fig. S2, arrows, third and fourth rows).
In three experiments, we again observed strongCD8+ responses
to aDNA boost in mice primed withDEC-gag p41 protein vaccine
plus polyIC but not control Ig gag p41 plus polyIC (Fig. 5A;
compare turquoise and dark blue). Importantly, when we replaced
the protein vaccine with peptides, only helper peptides recognized
by CD4+ T cells, and not the peptide recognized by gag-specific
CD8+Tcells, were able to prime for a strongCD8+Tcell response
to DNA gag vaccine (Fig. 5A, lower two rows). Thus, priming
CD4+ T cells with peptides allows for better CD8+ T cell
responses to a single dose of DNA vaccine. Next, to evaluate the
specificity of the help provided by CD4+ T cells, we immunized
CxB6 F1 mice with either HIV gag- or LCRV CD4-restricted
peptides and boosted withHIV gagDNAas above. Only gagCD4-
restricted peptides enhanced CD8+ T cell responses to gag DNA
vaccine (P< 0.03) (Fig. 5B; compare fifth and sixth rows, ** and *).
This indicated that help provided to CD8+ T cells was cognate
antigen-dependent.
Complementary Protein Prime-DNA Boost Vaccine Requires CD40. To
begin to understandmechanisms required for the helper effect of a
DC-targeted protein vaccine, we pursued the fact that helper T
cells express CD40L, which acts to mature DCs presenting anti-
gens to CD8+ T cells (10, 14–16). Indeed, CD40−/− mice devel-
oped reduced CD4+ and CD8+ T cell immunity to vaccination
with either two doses of DNA or complementary protein prime
DNA boost, including T cells that could proliferate and produce
IFN-γ in response to HIV gag antigen (Fig. S3; compare Left and
Right). Complementary prime boost did not allow for reduced
virus titers in lungs (Fig. 6A; compare fourth and fifth rows).When
we also followed CD8+T cell accumulation to a challenge site, the
CD40−/− mice lacked gag-specific CD8+ T cells in the lungs, with
either two DNA vaccines or the complementary prime boost
strategy (Fig. 6B; compare thick and thin arrows for wild-type and
CD40−/− mice). Thus, our prime boost vaccination increased lung
CD8+ T cells in a CD40-dependent manner.
To determine whether CD40 was operating at the level of
antigen-presenting cells, we adoptively transferred gag-primed
CD4+ T cells into wild-type or CD40−/− mice and then boosted
with DNA vaccine. Before T cell transfer, we first confirmed pri-
ming of gag-specific CD4+T cells in the donormice (Fig. S4). One
day later themicewere boostedwith a single dose of gagDNA, and
4weeks later themicewere challenged i.n. with vaccinia gag.Upon
challenge, wild-type, but not CD40−/−, mice showed a 10 log-fold
reduction in lung virus titer when provided with immune CD4+ T
cells [Fig. 6C; compare two left blue bars (P < 0.018)]. Thus,
adoptively transferred wild-type CD4+ T cells do not enhance the
protection afforded by a DNA vaccine in CD40−/− mice.
Discussion
Protein and DNA vaccines, though safe, do not induce a high
frequency of CD4+ and CD8+ T cells as detected by cytokine
production and cell proliferation. Our results show that antigen-
specific CD4+ helper T cells can be elicited by a priming dose of a
DEC-targeted protein vaccine, and this improves the induction of
T cell immunity with a DNA vaccine. In addition to strong, com-
bined, durableT cell immunity, this approach improvedprotection
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Fig. 5. Helper HIV gag peptides improve CD8 T cell responses to DNA vaccine. Two experiments in which CxB6 F1 mice were vaccinated as in Figs. 2 and 3, but
we added groups of mice primed with HIV gag peptides recognized by CD4+ and CD8+ T cells, or LcrV CD4-restricted peptides, to compare with DEC gag p41
protein vaccine (y axis). Thirty days after the DNA vaccine boost we measured HIV gag-specific IFN-γ-producing CD4+ and CD8+ IFN-γ-secreting T cells, and
tetramer binding CD8+ T cells. Shown are means of two experiments.

































airway. We are also finding that the DNA vaccine can either pre-
cede or follow the DEC-gag protein vaccine.
Multiple strategies have been exploited to augment the
induction of effective immunity following DNA vaccination
(reviewed in refs. 17–19), including the coadministration of toll-
like receptor ligands (20). Importantly, in prime boosted mice
challenged with vaccinia gag, the CD8+ gag-specific T cells
induced by our complementary prime boost approach were more
rapidly mobilized in the lung. A similar finding has been reported
in an elegant report carried out during our study; i.e., that helper
cells formed during infection improved the influx of CD8+ T cells
to the infection site (21).
CD4+ helper cells are known to improve CD8+ T cell immunity
(reviewed in ref. 22). CD4+ T cells can provide IL-2 required to
sustain CD8+ T cell memory, although these CD4+ T cells do not
have to be primed to a specific antigen (23). Alternatively, Heath
et al. (24), in studies of the strong CD8+ T cell response to influ-
enza and HSV, showed that CD4+ and CD8+ T cells each had to
respond to the same antigenic component of the virus. We also
found, consistent with previous data (24, 25), that the CD4+ and
CD8+T cells needed to recognize peptides from the same protein.
With respect to mechanism, CD40 was required for the pro-
tective efficacy of the complementary prime boost vaccination.
CD40L is expressed by CD4+ helper T cells, and one consequence
of CD40L function is to ligate CD40 on DCs, driving their matu-
ration and enhancing immunity to antigens presented by DCs (10,
14–16). In addition, intravital microscopy of intact lymph nodes
indicates that CD4+ helper cells recruit CD8+ T cells to the
antigen presenting DCs (26) by producing CCL3 and CCL4 che-
mokines (27), the same chemokines that block HIV infection via
CCR5 coreceptors (28). We verified that the helper effect from
priming CD4+ T cells operated through CD40 on non-T cells,
presumably DCs. In addition, we found that CD40-mediated help
led to the more rapid accumulation of CD8+ T cells at a site of
challenge infection, the lung.
There is concern thatHIV-specificCD4+Tcells could provide a
permissive environment for HIV replication (29), but the recip-
rocal is also possible, that CD4+ helper cells produce chemokines
that block the CCR5 coreceptor (30) and, as we emphasize here,
valuably help protective CD8+ T cell (and antibody) responses
(31). In particular, antigen-specific CD4+ T cells allow for the
more rapid accumulation of antigen-specific CD8+ T cells after
challengewith apathogenic virus. Inmacaques showingprotection
after vaccination with attenuated delta nef SIV vaccine (32) or
recombinant adenovirus-SIV gag (33), broad gag-specific CD4+ T
cell immunity was evident, raising the possibility that gag-specific
CD4+ T cells can be helpful, not harmful, in resisting immuno-
deficiency virus. A key distinction is that the CD4+ T cells should
be virus-specific to provide help for strong protective CD8+
resistance as opposed to more abundant activated T cells specific
for disparate antigens, which can serve as a permissive site for SIV
and HIV but fail to offer protective value.
Thecomplementaryprimeboost approach, inwhichDC-targeted
protein vaccine favors helper cell formation and DNA vaccine
favors killer cell formation, does not require microbial vectors, thus
simplifying vaccine manufacture; it also reduces antivector
immunity as well as competition between peptides presented from
vector and vaccine antigens. By directing the helper response to
defined proteins, it may be feasible to improve the quality of the
CD8+ T cell response to DNA and other vaccines, and potentially
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Fig. 6. Help from DC-targeted protein vaccine requires CD40. (A) Female wild-type and CD40−/− CxB6 F1 mice were vaccinated as indicated on the y axis.
Thirty days after the last DNA boost mice were challenged with vaccinia gag i.n. to assess protection in terms of body weight and lung virus titers as in Fig. 1.
(B) Likewise, during the challenge with vaccinia gag the numbers of CD8+ gag-specific tetramer binding cells were measured at day 4 and day 7 in spleen and
lungs. (C) Female CxB6 F1 mice were vaccinated with DEC-p41 and polyIC twice. A spleen equivalent of CD4
+ T cells was then adoptively transferred into wild-
type or CD40−/− CxB6 F1 mice and boosted with a single dose of HIV gag DNA. Four weeks later the mice were challenged with vaccinia gag. Data represent a
mean ± SD of 10 mice per group.










































Mice and DNA Vaccination. CxB6 F1 mice from Harlan were maintained under
specific-pathogen-free conditions and used at 6–10 weeks, according to
Rockefeller University guidelines. DNA vaccine (prepared with Qiagen endo-
toxin free GIGA kit) was injected i.m. in saline with electroporation (Ichor
Medical Systems) and 1.25 mg per mouse nembutal anesthesia i.p. The skin
above the anterior tibialis muscles was shaved and sterilized with ethanol.
Antibodies. Antibodies toCD3,CD4,CD8α, andcytokines (IFN-γ, IL-2,andTNF-α)
were purchased from BD Biosciences-Pharmingen.
Fusion HIV gag mAbs. These were generated as described (4, 5). Western
blotting with HRP-anti-p24 (ImmunoDiagnostics) was used to determine the
specificity of the gag fusion constructs. mAb bindingwas verified on CHO cells
stably transfected with mouse DEC-205 by FACS, using either PE-conjugated
goat anti-mouse IgG (Jackson ImmunoResearch) or FITC-conjugated anti-p24
(Coulter KC57-FITC). All mAbs were endotoxin-free in limulus amebocyte
lysate assay (QCL-1000; Cambrex).
Immunizations. Female CXB6 F1 mice were injected once i.p. with fusion mAb
together with polyIC (50 μg; Invivogen) as adjuvant. Eight weeks later, mice
were boosted with 10 μg of HIV gag p41 DNA. One hundred micrograms of
peptides was injected i.m. with or without polyIC. Four weeks after the last
peptide injection, mice were boosted with 10 μg of HIV gag p41 DNA.
Assays for HIV-Specific Immune T Cells. To detect HIV gag–specific T cell
responses, bulk splenocytes were restimulated with peptides spanning the
entire gagp41 sequence (4, 5, 12) or a negative unreactive control peptidemix
consisting of HIV gag p17 pool 1 in the presence of 2 μg/mL anti-CD28 (clone
37.51) for 6 h, adding 10 μg/mL brefeldin A (Sigma-Aldrich) for the last 4 h to
accumulate intracellular cytokines. Overlapping (staggered by 4 aa) 15-mer
peptides spanning LcrV (13) and HIV gag p41—i.e., HIV gag p17 and HIV gag
p24 (4)—were synthesized by the Proteomic Resource Center (The Rockefeller
University). The 90-member gag p41 library was resuspended at 1mg/mL each
peptide in 100% DMSO. For FACS, dead cells were excluded using LIVE/DEAD
fixable dead stain kit (Aqua LIVE/DEAD; Invitrogen). After blocking Fcγ
receptors, the cells were stained with antibodies to CD3-pacific blue, CD4-
percp, CD8-alexa-750, andAqua LIVE/DEAD stain for 20minat 37 °C. Cellswere
washed, fixed (Cytofix/Cytoperm; BD Biosciences), permeabilized with Perm-
wash and stained with antibodies to IFN-γ (IFN-γ-alexa-700), IL-2 (IL-2-FITC),
andTNF-α (TNF-α-PE-CY7) for 15minat roomtemperature.All antibodieswere
from eBioscience, and HIV gag CD8 tetramers (AMQMLKETI) were H-2Kd PE
from Beckman Coulter. We use BD Biosciences LSRII with data analysis in
FlowJo (Tree Star).
Vaccinia gag Protection Assays. Nembutal-anesthetizedmicewere challenged
i.n.with 105 PFUpermouse recombinant vaccinia gag virus in 35 μL of PBSwith
Mg/Ca. A negative control was vaccinia-OVA virus. Animal weights (groups of
five) were determined daily for 7 days following challenge. Then, mice were
euthanized, and their lungs were harvested, homogenized in transport
medium (0.1% gelatin in PBS), and stored in duplicate at –80 °C before virus
titration. Lungvirus titers of individualmice ineachgroupweredeterminedby
plaque assay on monolayers of CV-1 cells as described (4, 5, 12).
Statistics. Postchallenge mean vaccinia lung virus titers and mean percentage
in weight loss were compared between vaccination groups using one-tailed
Student’s t test. Differences were considered significant at P < 0.05 after
analysis using Prism 3 (GraphPad).
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